Biosyent Inc
XTSX:RX
Biosyent Inc
XTSX:RX
Price:
15.56
CAD
-0.89%
Market Closed
Market Cap:
CA$178.6m
Relative Value
The Relative Value of one
RX
stock under the Base Case scenario is
9.66
CAD.
Compared to the current market price of 15.56 CAD,
Biosyent Inc
is
Overvalued by 38%.
Relative Value is the estimated value of a stock based on various valuation multiples like P/E and EV/EBIT ratios. It offers a quick snapshot of a stock's valuation in relation to its peers and historical norms.
Relative Valuation FAQ:
RX
Relative Value
Base Case
9.66
CAD
Overvaluation 38%
Multiples Across Competitors
RX Competitors Multiples
Biosyent Inc Competitors
Biosyent Inc Competitors
All Countries
| Market Cap | P/S | P/E | EV/EBITDA | EV/EBIT | ||||
|---|---|---|---|---|---|---|---|---|
| CA |
|
Biosyent Inc
XTSX:RX
|
175.2m CAD | 4.2 | 20.3 | 13 | 14.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
952.7B USD | 14.6 | 46.2 | 31.1 | 33.2 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
584.1B USD | 6.2 | 21.8 | 15.1 | 18.6 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
262.5B CHF | 4.3 | 20.4 | 12 | 13.6 | |
| CH |
|
Novartis AG
SIX:NOVN
|
238.2B CHF | 5.5 | 22.1 | 13.7 | 17.5 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
223.5B GBP | 5.1 | 29.3 | 16.2 | 22.9 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
289.8B USD | 4.5 | 15.9 | 9.9 | 12 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
218B USD | 94 | -74.6 | 344.9 | 865 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 3.6 | 10.9 | 8.1 | 9.5 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
152.4B USD | 2.4 | 19.6 | 7.6 | 10.1 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
122B USD | 2.5 | 17.3 | 7.3 | 9 |
P/S Multiple
P/E Multiple
EV/EBITDA Multiple
EV/EBIT Multiple
